Amarex Clinical Research Site Passes Surprise FDA Audit for a Multicenter, Randomized-Controlled Clinical Trial in Surgical Wound Healing and Cosmesis Study Submitted to FDA for Approval

Amarex and SyneuRx announce FDA approval of Breakthrough designation for Schizophrenia treatment

Amarex Founder and CEO Dr. Kazem Kazempour appointed to George Washington University's Regulatory Affairs Advisory Board

Successful FDA Meeting Advances Botonical Drug to Phase II Study